Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States

References

• Luo SY, Lam DC. Oncogenic driver mutations in lung cancer. Transl Respir Med 2013;1:6
   PubMedGoogle Scholar
• Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn 2016;16:737-49
   PubMed Web of Science ®Google Scholar
• Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016;8:32-47
   PubMed Web of Science ®Google Scholar
• Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012;13:1376-83
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. 2016. Available at: http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer
   Google Scholar
• Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol 2016;9:19
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17
   PubMed Web of Science ®Google Scholar
• Soria J, Tan D, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-29
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim D-W, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2017;12:1357-67
   PubMed Web of Science ®Google Scholar
• Balu S, Cerezo-Camacho O, Smith NJ, et al. Cost-effectiveness of ceritinib versus current therapies for chemotherapy-experienced anaplastic lymphoma kinase positive non-small cell lung cancer patients in Mexico. Value Health 2015;18:A821
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Canestaro W, Ravelo A, et al. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. J Med Econ 2017;20:671-7
   PubMed Web of Science ®Google Scholar
• Hurry M, Zhou ZY, Zhang J, et al. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. J Med Econ 2016;19:936-44
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang J, Fan L, et al. Cost-effectiveness of ceritinib in the treatment of previously treated anaplastic lymphoma kinase-positive (Alk+) non-small cell lung cancer in the United Kingdom. Value Health 2015;18:A455-A6
   PubMed Web of Science ®Google Scholar
• NICE. Crizotinib for the second line treatment of ALK positive non-small cell lung cancer (TA296; manufacturer’s submission).NICE; 2012. Available at: http://www.nice.org.uk/guidance/ta296/resources/lung-cancer-nonsmallcell-anaplastic-lymphoma-kinase-fusion-gene-previously-treated-crizotinib-pfizer2
   Google Scholar
• NICE. Single technology appraisal: Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865] Committee Papers. NICE; 2016. Available at: https://www.nice.org.uk/guidance/TA406/documents/committee-papers-2
   Google Scholar
• NICE. Technical appraisal guidance [TA347]: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE; 2015. https://www.nice.org.uk/guidance/ta347/chapter/1-Guidance
   Google Scholar
• pCODR. Expert review committee (pERC) final recommendation: Nivolumab (Opdivo). pCODR; 2016. Available at: https://www.cadth.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_rec.pdf
   Google Scholar
• pCODR. pERC initial recommendation: Pembrolizumab (Keytruda). pCODR; 2016. Available at: https://www.cadth.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf
   Google Scholar
• pCODR. pan-Canadian funding summary: Crizotinib (Xalkori) for advanced non-small cell lung cancer. pCODR; 2014. Available at: http://www.pcodr.ca/idc/groups/pcodr/documents/webcontent/pcodr-provfund_xalkorire-nsclc.pdf
   Google Scholar
• pCODR. Final economic guidance report: Afatinib (Giotrif) for advanced non-small cell lung cancer. pCODR; 2014. Available at: https://www.cadth.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-egr.pdf
   Google Scholar
• Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001;2:259-78
   Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Solomon B, Mok T, Kim D, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77
   PubMed Web of Science ®Google Scholar
• Felip E, Blackhall FH, Mok T, et al. Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). Poster Presentation. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL. May 29–June 2, 2015. J Clin Oncol 2015;33(suppl);abstr 8101
   Google Scholar
• Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol 2013;8:997-1003
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. Micromedex solutions, Red Book. Truven Health Analytics; 2017. Available at: http://www.micromedexsolutions.com/micromedex2/librarian/
   Google Scholar
• Novartis Pharmaceuticals Corporation. Prescribing Information for Zykadia (ceritinib). Novartis Pharmaceuticals Corporation; 2016. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/zykadia.pdf
   Google Scholar
• Pfizer Labs. Prescribing information for Xalkori (crizotinib). Pfizer Labs; 2017. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=676
   Google Scholar
• Australian Department of Health TGA. Australian public assessment report for crizotinib. Attachment 3: Extract from the clinical evaluation report of study A8081007. ADH; 2013. Available at: https://www.tga.gov.au/sites/default/files/auspar-crizotinib-130620-att3-cer.pdf
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule. Centers for Medicare & Medicaid Services; 2017. Available at: http://www.cms.gov/apps/physician-fee-schedule/overview.aspx
   Google Scholar
• Eli Lilly and Company. Prescribing information for Alimta (pemetrexed). Eli Lilly and Company; 2004. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021677lbl.pdf
   Google Scholar
• Teva Parenteral Medicines. Prescribing information for Carboplatin injection. Teva Parenteral Medicines; 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/077139Orig1s016lbl.pdf
   Google Scholar
• Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004;12:219-26
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS). US DoHHS; 2014. Available at: https://hcupnet-archive.ahrq.gov/HCUPnet.jsp
   Google Scholar
• US Department of Labor BoLS. Consumer Price Index - All Urban Consumers. Medical Care Component. US DoL; 2017. https://data.bls.gov/cgi-bin/dsrv?ap
   Google Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care 2008;14:565-71
   PubMed Web of Science ®Google Scholar
• Prescribing Information for Alimta (pemetrexed). Indianapolis, IN: Eli Lilly and Company; 2004. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021677lbl.pdf
   Google Scholar
• Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-87
   PubMed Web of Science ®Google Scholar
• Felip E, Orlov S, Park K, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:Abstract no. 8060
   Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
   PubMed Web of Science ®Google Scholar
• Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non–small-cell lung cancer. J Clin Oncol 2009;27:1836-43
   PubMed Web of Science ®Google Scholar
• Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract 2012;8:75s-80s
   PubMedGoogle Scholar
• Institute for Clinical and Economic Review (ICER). Final value assessment framework for 2017–2019. ICER; 2017. Available at: https://icer-review.org/final-vaf-2017-2019/
   Google Scholar
• NCCN. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 8. NCCN; 2017. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Truven Health Analytics. RED BOOK Online Search. Truven Health Analytics; 2017. Available at: http://www.micromedexsolutions.com/micromedex2/librarian
   Google Scholar